BiotechTV

𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬 𝐰𝐢𝐭𝐡 𝐂𝐡𝐫𝐢𝐬 𝐆𝐚𝐫𝐚𝐛𝐞𝐝𝐢𝐚𝐧: Episode 9 | Alloy Therapeutics, Inc. & 82VS's Errik Anderson. He describes his career path and learnings from the tech industry, co-founding Adimab, the work that Alloy and 82VS do to support and invest in scientist-entrepreneurs, and why he believes smaller organizations are best suited for discovery work and other early stage innovation. Full video: https://lnkd.in/g7zPQhjG BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝: Heather Turner and Sheila Gujrathi, MD discuss managing your board of directors effectively. Interviewed by Biotech CEO Sisterhood editorial board member Sheila Gujrathi, former Carmot Therapeutics, Inc. CEO and newly named CEO of LB Therapeutics Heather Turner talks about communications skills and other best practices for CEOs to have an effective working relationship with their board of directors. Full video: https://lnkd.in/gmNMdmBK BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: PureTech Health's CEO and Co-Founder discuss this week's IPF data, the approval of Cobenfy in schizophrenia, and the company's unique hub and spoke business model. CEO Bharatt Chowrira and Co-Founder Eric Elenko describe the unmet need in IPF that exists today, and how their drug deupirfenidone was tested against the standard of care in this phase 2b study. Plus, inventing Cobenfy, and what PureTech's 'Founded Entities' are working on today. Full video: https://lnkd.in/ggyY7-Tn BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Baird biotech analyst Jack Allen, CFA recaps #ASH24 and other recent news, and shares his outlook for top names in 2025. He discusses data that Arcellx and Vor had at last week's ASH annual meeting, and discusses Mereo, Ultragenyx, Instil Bio, Taysha Gene Therapies, and more. Full video: https://lnkd.in/gXNnnG_R BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Cardiff Oncology's CEO Mark Erlander, Ph.D. discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC. He describes the rationale for PLK1 inhibition and highlights the significance of the data, which will have an additional update next year. Plus, where Cardiff believes it can go beyond colorectal cancer with this asset. Full video: https://lnkd.in/g_uwXSjb BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Dimension's Zavain Dar talks about raising a $500M second fund, and describes the firm's ethos of investing in companies that are highly focused in both life sciences and technology. He discusses the founding of Dimension, and highlights entrepreneurs and portfolio companies that have matched the firm's focused investment objective. Full video: https://lnkd.in/g7sQ9Nvt BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Syndax Pharmaceuticals' CEO Michael A. Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more. He describes being first to market in the menin inhibitor space and the advantage he believes that gives Syndax, and he highlights other recent data from the program. Plus, the immanent launch of Niktimvo, doing a deal with Royalty Pharma, and how he believes GVHD can be a substantial market. Full video: https://lnkd.in/gcSJNApe BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬 𝐰𝐢𝐭𝐡 𝐂𝐡𝐫𝐢𝐬 𝐆𝐚𝐫𝐚𝐛𝐞𝐝𝐢𝐚𝐧: Episode 8 | Canaan's Julie Grant. A general partner the firm, she describes her career path, including time spent at Goldman Sachs and Genentech, before landing at Canaan over a decade ago. She discusses the firm's investment approach to healthcare, and boldly moving into new categories of medicine even in cases where an organization doesn't have existing commercial infrastructure. Full video: https://lnkd.in/gC9tFGRC BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐒𝐞𝐚𝐭𝐭𝐥𝐞: Seal Rock Therapeutics is working on a second-generation ASK1 inhibitor that is designed to improve on the safety profile of the class and could have utility in a range of liver diseases. Co-founder and CEO Neil McDonnell describes the history of ASK1 and how Seal Rock's program has been optimized to avoid roadblocks that pharma companies experienced in the past. He explains how the company is currently putting it to use in cirrhosis, liver failure (with partner Genfit), and in CNS conditions (along with LRRK2). Full video: https://lnkd.in/ga6fRQfQ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐒𝐞𝐚𝐭𝐭𝐥𝐞: Nautilus Biotechnology is developing a platform that aims to revolutionize how researchers are able to see the proteome. CEO Sujal Patel tells us how it will work. He describes the shortcomings of high affinity assays and mass spectometry, and how the Nautilus system will be different. Plus, use cases, including recent work on the tau protein he says has caught the attention of drug developers. The device is scheduled to be commercially available approximately late next year. Full video: https://lnkd.in/gE7zfyAZ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh